An early-stage HER2-positive (HER2+) breast cancer is always a shock, but today’s treatment options should give you hope. Over the past 2 decades, advances in medicine have brought us new ...

2:02 | So, 66% in terms of an intracranial response rate is very high and really the highest that we have ever seen for an ...

Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

You've just been diagnosed with HER2+ breast cancer, and you're wondering what happens next. Every person is different, but here’s what treatment generally looks like and what milestones you can ...

Treatment for breast cancer can come in many forms. In addition to surgery to remove cancerous tissue and radiation therapy, ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

Bile duct cancer is rare, treatment options are limited, and the survival rates are low. The trial also suggests that a wider group of breast cancer patients—those with HER2-mutated breast ...

RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE ...

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

Cite this: The Role of Hormonal Therapy in the Management of Hormonal-Receptor-Positive Breast Cancer With Co-Expression of HER2 - Medscape - Sep 01, 2008. The article is based primarily on a ...

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of ...

The novel treatment approach may allow for chemotherapy de-escalation in select patients, offering a potential new therapeutic strategy. Patients with TNBC and HR+/HER2- breast cancer demonstrated ...